Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial.

Background: Abrupt cessation of alcohol intake causes habituated drinkers to experience symptoms of alcohol withdrawal syndrome (AWS).

Objective: To determine the effect of the gamma-aminobutyric acid (GABA)-B agonist baclofen on the course of acute symptomatic AWS.

Design: Prospective, randomized, double-blind, placebo-controlled clinical study.